title: Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group.
abstract: BACKGROUND
  The Lennox-Gastaut syndrome, a severe form of epilepsy that usually begins in early childhood, is difficult to treat. Dose-related drug toxicity is common.
  
  
  METHODS
  We conducted a double-blind, placebo-controlled trial of the antiepileptic drug lamotrigine in patients with the Lennox-Gastaut syndrome. Eligible patients had more than one type of predominantly generalized seizure, including tonic-clonic, atonic, tonic, and major myoclonic, and had seizures on average at least every other day. After a 4-week base-line period in which all participants received placebo, we randomly assigned 169 patients (age range, 3 to 25 years) to 16 weeks of lamotrigine (n= 79) or placebo (n=90) in addition to their other antiepileptic drugs.
  
  
  RESULTS
  The median frequency of all major seizures changed from base-line levels of 16.4 and 13.5 per week in the lamotrigine and placebo groups, respectively, to 9.9 and 14.2 per week after 16 weeks of treatment (P=0.002). Thirty-three percent of the patients in the lamotrigine group and 16 percent of those in the placebo group had a reduction of at least 50 percent in the frequency of seizures (P= 0.01). There were no significant differences between groups in the incidence of adverse events, except for colds or viral illnesses, which was more common in the lamotrigine group (P=0.05).
  
  
  CONCLUSIONS
  Lamotrigine was an effective and well-tolerated treatment for seizures associated with the Lennox-Gastaut syndrome.
authors.affiliation: American Memorial Hospital, Hôpital d'Enfants, Reims, France.
authors.forename: J
authors.initials: J
authors.lastname: Motte
authors.forename: E
authors.initials: E
authors.lastname: Trevathan
authors.forename: J F
authors.initials: JF
authors.lastname: Arvidsson
authors.forename: M N
authors.initials: MN
authors.lastname: Barrera
authors.forename: E L
authors.initials: EL
authors.lastname: Mullens
authors.forename: P
authors.initials: P
authors.lastname: Manasco
mesh_terms: D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008607:Intellectual Disability; D000077213:Lamotrigine; D008297:Male; D012640:Seizures / Q000188:drug therapy; D013577:Syndrome; D016896:Treatment Outcome; D014227:Triazines / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000927:Anticonvulsants; D014227:Triazines; D000077213:Lamotrigine